Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Dyax Corp. announced that Wyeth Pharmaceuticals, a division of Wyeth, recently received market approval from the U.S. food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis. The peptide ligand, used in the purification process during the manufacture of XYNTHA, was discovered utilizing Dyax's proprietary phage display library and is part of the Company's Licensing and Funded Research Program (LFRP). XYNTHA is now distinguished as the only recombinant factor VIII treatment to utilize an entirely synthetic purification process.
Under the terms of the license agreement with Wyeth, Dyax is entitled to a milestone payment triggered by the first commercial sale of XYNTHA followed by royalties based on certain pre-determined sales levels.
Other news from the department research and development
